325 related articles for article (PubMed ID: 28108737)
21. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
22. Akt pathway as a target for therapeutic intervention in HNSCC.
Moral M; Paramio JM
Histol Histopathol; 2008 Oct; 23(10):1269-78. PubMed ID: 18712679
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
Papaspyrou G; Werner JA; Dietz A
Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
[TBL] [Abstract][Full Text] [Related]
24. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Bancroft CC; Chen Z; Yeh J; Sunwoo JB; Yeh NT; Jackson S; Jackson C; Van Waes C
Int J Cancer; 2002 Jun; 99(4):538-48. PubMed ID: 11992543
[TBL] [Abstract][Full Text] [Related]
25. Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.
Gong W; Xiao Y; Wei Z; Yuan Y; Qiu M; Sun C; Zeng X; Liang X; Feng M; Chen Q
Oncotarget; 2017 Jan; 8(2):2141-2152. PubMed ID: 27924064
[TBL] [Abstract][Full Text] [Related]
26. Axitinib in the Treatment of Head and Neck Malignancies.
Swiecicki PL; Spector M; Worden FP
Curr Clin Pharmacol; 2016; 11(2):72-6. PubMed ID: 27188575
[TBL] [Abstract][Full Text] [Related]
27. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
Blaszczak W; Barczak W; Wegner A; Golusinski W; Suchorska WM
Med Oncol; 2017 Apr; 34(4):60. PubMed ID: 28315228
[TBL] [Abstract][Full Text] [Related]
30. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Bensen R; Brognard J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799513
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck.
Mangano A; Mangano A; Lianos GD; Roukos DH; Caprioglio A; Dionigi G
Future Oncol; 2015; 11(1):9-12. PubMed ID: 25572780
[No Abstract] [Full Text] [Related]
32. Novel targeted therapies in head and neck cancer.
Ferreira MB; Lima JP; Cohen EE
Expert Opin Investig Drugs; 2012 Mar; 21(3):281-95. PubMed ID: 22239178
[TBL] [Abstract][Full Text] [Related]
33. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
35. New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
De Felice F; Guerrero Urbano T
Oral Oncol; 2017 Apr; 67():119-123. PubMed ID: 28351565
[TBL] [Abstract][Full Text] [Related]
36. Genetic deregulation of the PIK3CA oncogene in oral cancer.
Murugan AK; Munirajan AK; Tsuchida N
Cancer Lett; 2013 Sep; 338(2):193-203. PubMed ID: 23597702
[TBL] [Abstract][Full Text] [Related]
37. Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
Yarbrough WG; Whigham A; Brown B; Roach M; Slebos R
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S98-101. PubMed ID: 17848307
[TBL] [Abstract][Full Text] [Related]
38. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Lui VW; Hedberg ML; Li H; Vangara BS; Pendleton K; Zeng Y; Lu Y; Zhang Q; Du Y; Gilbert BR; Freilino M; Sauerwein S; Peyser ND; Xiao D; Diergaarde B; Wang L; Chiosea S; Seethala R; Johnson JT; Kim S; Duvvuri U; Ferris RL; Romkes M; Nukui T; Kwok-Shing Ng P; Garraway LA; Hammerman PS; Mills GB; Grandis JR
Cancer Discov; 2013 Jul; 3(7):761-9. PubMed ID: 23619167
[TBL] [Abstract][Full Text] [Related]
39. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Amornphimoltham P; Sriuranpong V; Patel V; Benavides F; Conti CJ; Sauk J; Sausville EA; Molinolo AA; Gutkind JS
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4029-37. PubMed ID: 15217935
[TBL] [Abstract][Full Text] [Related]
40. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
